40
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Regulation of I κB α Function and NF- κB Signaling: AEBP1 Is a Novel Proinflammatory Mediator in Macrophages

      review-article
      1 , * , 2
      Mediators of Inflammation
      Hindawi Publishing Corporation

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          NF- κB comprises a family of transcription factors that are critically involved in various inflammatory processes. In this paper, the role of NF- κB in inflammation and atherosclerosis and the regulation of the NF- κB signaling pathway are summarized. The structure, function, and regulation of the NF- κB inhibitors, I κB α and I κB β, are reviewed. The regulation of NF- κB activity by glucocorticoid receptor (GR) signaling and I κB α sumoylation is also discussed. This paper focuses on the recently reported regulatory function that adipocyte enhancer-binding protein 1 (AEBP1) exerts on NF- κB transcriptional activity in macrophages, in which AEBP1 manifests itself as a potent modulator of NF- κB via physical interaction with I κB α and a critical mediator of inflammation. Finally, we summarize the regulatory roles that recently identified I κB α-interacting proteins play in NF- κB signaling. Based on its proinflammatory roles in macrophages, AEBP1 is anticipated to serve as a therapeutic target towards the treatment of various inflammatory conditions and disorders.

          Related collections

          Most cited references356

          • Record: found
          • Abstract: found
          • Article: not found

          Function and activation of NF-kappa B in the immune system.

          NF-kappa B is a ubiquitous transcription factor. Nevertheless, its properties seem to be most extensively exploited in cells of the immune system. Among these properties are NF-kappa B's rapid posttranslational activation in response to many pathogenic signals, its direct participation in cytoplasmic/nuclear signaling, and its potency to activate transcription of a great variety of genes encoding immunologically relevant proteins. In vertebrates, five distinct DNA binding subunits are currently known which might extensively heterodimerize, thereby forming complexes with distinct transcriptional activity, DNA sequence specificity, and cell type- and cell stage-specific distribution. The activity of DNA binding NF-kappa B dimers is tightly controlled by accessory proteins called I kappa B subunits of which there are also five different species currently known in vertebrates. I kappa B proteins inhibit DNA binding and prevent nuclear uptake of NF-kappa B complexes. An exception is the Bcl-3 protein which in addition can function as a transcription activating subunit in th nucleus. Other I kappa B proteins are rather involved in terminating NF-kappa B's activity in the nucleus. The intracellular events that lead to the inactivation of I kappa B, i.e. the activation of NF-kappa B, are complex. They involve phosphorylation and proteolytic reactions and seem to be controlled by the cells' redox status. Interference with the activation or activity of NF-kappa B may be beneficial in suppressing toxic/septic shock, graft-vs-host reactions, acute inflammatory reactions, acute phase response, and radiation damage. The inhibition of NF-kappa B activation by antioxidants and specific protease inhibitors may provide a pharmacological basis for interfering with these acute processes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation.

            Nuclear factor-kappaB (NF-kappaB) is a transcription factor that has crucial roles in inflammation, immunity, cell proliferation and apoptosis. Activation of NF-kappaB mainly occurs via IkappaB kinase (IKK)-mediated phosphorylation of inhibitory molecules, including IkappaBalpha. Optimal induction of NF-kappaB target genes also requires phosphorylation of NF-kappaB proteins, such as p65, within their transactivation domain by a variety of kinases in response to distinct stimuli. Whether, and how, phosphorylation modulates the function of other NF-kappaB and IkappaB proteins, such as B-cell lymphoma 3, remains unclear. The identification and characterization of all the kinases known to phosphorylate NF-kappaB and IkappaB proteins are described here. Because deregulation of NF-kappaB and IkappaB phosphorylations is a hallmark of chronic inflammatory diseases and cancer, newly designed drugs targeting these constitutively activated signalling pathways represent promising therapeutic tools.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              An essential role for NF-kappaB in preventing TNF-alpha-induced cell death.

              Studies on mice deficient in nuclear factor kappa B (NF-kappaB) subunits have shown that this transcription factor is important for lymphocyte responses to antigens and cytokine-inducible gene expression. In particular, the RelA (p65) subunit is required for induction of tumor necrosis factor-alpha (TNF-alpha)-dependent genes. Treatment of RelA-deficient (RelA-/-) mouse fibroblasts and macrophages with TNF-alpha resulted in a significant reduction in viability, whereas RelA+/+ cells were unaffected. Cytotoxicity to both cell types was mediated by TNF receptor 1. Reintroduction of RelA into RelA-/- fibroblasts resulted in enhanced survival, demonstrating that the presence of RelA is required for protection from TNF-alpha. These results have implications for the treatment of inflammatory and proliferative diseases.
                Bookmark

                Author and article information

                Journal
                Mediators Inflamm
                MI
                Mediators of Inflammation
                Hindawi Publishing Corporation
                0962-9351
                1466-1861
                2010
                12 April 2010
                : 2010
                : 823821
                Affiliations
                1Department of Biology and Chemistry, Faculty of Arts and Sciences, American University of Sharjah, P.O. Box 26666, Sharjah, UAE
                2Department of Biochemistry and Molecular Biology, Faculty of Medicine, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, NS, Canada B3H 1X5
                Author notes
                *Amin Majdalawieh: amajdalawieh@ 123456aus.edu

                Academic Editor: Hidde Bult

                Article
                10.1155/2010/823821
                2855089
                20396415
                c14404c5-f532-43d0-b4d4-a6d93082a705
                Copyright © 2010 A. Majdalawieh and H.-S. Ro.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 17 November 2009
                : 12 January 2010
                Categories
                Review Article

                Immunology
                Immunology

                Comments

                Comment on this article